Compare Moody's Corporation (MCO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Mesoblast Limited — how do they compare? Moody's Corporation trades at $496.27 (market cap $88.28B), while Mesoblast Limited trades at $16.32 (market cap $2.17B). The key difference: Moody's Corporation is far larger — about 40.7× Mesoblast Limited's market cap, and Moody's Corporation pays a 0.82% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MCO | MESO | |
|---|---|---|
Market Cap | $88.28B | $2.17B |
Sector | Financials | Technology |
52-Week High | $539.61 | $20.96 |
52-Week Low | $412.23 | $12.88 |
Enterprise Value | $94.08B | $2.17B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $505.12, down 1.12% today, with a bullish technical signal from moving averages but overbought RSI readings near 76. The company shows strong fundamentals with Q1 2026 EPS beating estimates at $4.33, revenue growth to $7.72B in 2025, and robust profitability margins including a 31.69% net income margin. Recent news highlights AI integration initiatives and dividend sustainability, with a $1.03 dividend paid in June 2026.
Outlook remains positive given analyst consensus of $551.17 price target and 56% buy ratings, though valuation multiples like P/E of 36.65 pose risks if growth slows. Key risks include high debt levels and market sensitivity to credit cycles, but institutional support and recurring revenue model provide stability for long-term investors.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
